Trofinetide
Phase 2/3Terminated 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rett Syndrome
Conditions
Rett Syndrome
Trial Timeline
Sep 22, 2021 → May 31, 2023
NCT ID
NCT04988867About Trofinetide
Trofinetide is a phase 2/3 stage product being developed by Acadia Pharmaceuticals for Rett Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT04988867. Target conditions include Rett Syndrome.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04988867 | Phase 2/3 | Terminated |
| NCT04776746 | Phase 3 | Terminated |
| NCT04279314 | Phase 3 | Completed |
| NCT04181723 | Phase 3 | Completed |
Competing Products
20 competing products in Rett Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Esomeprazole + Aspirin + Rofecoxib | AstraZeneca | Approved | 85 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Esomeprazole Magnesium | AstraZeneca | Approved | 85 |
| AZD5213 and placebo | AstraZeneca | Phase 2 | 52 |
| fingolimod (FTY720) | Novartis | Phase 1/2 | 41 |
| PF-03654746 + Placebo + Placebo + PF-03654746 | Pfizer | Phase 2 | 51 |
| Aripiprazole | Bristol Myers Squibb | Pre-clinical | 22 |
| NBI-98854 | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 | Neurocrine Biosciences | Phase 1 | 30 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Abobotulinum toxin A | Ipsen | Pre-clinical | 20 |
| GWP42003-P + Placebo | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| trofinetide | Acadia Pharmaceuticals | Phase 3 | 72 |
| Trofinetide | Acadia Pharmaceuticals | Phase 3 | 72 |